Rafael Holdings, Inc. stock is up 2.84% since 30 days ago. The next earnings date is Dec 22, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November.
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies and commercial real estate assets. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.